Probiotic and Peanut Oral Immunotherapy Studies (PPOIT)
The prevalence of food allergy has increased, particularly in westernised countries. The need for a curative treatment is greatest for peanut allergy because this is usually life-long and the most common cause of anaphylaxis-related fatality. Oral immunotherapy (OIT) has been explored as a strategy to induce tolerance to food allergens.
The PPOIT (probiotic and peanut oral immunotherapy) trials are a series of studies investigating the use of the probiotic Lactobacillus rhamnosus and peanut OIT to induce sustained unresponsiveness to peanut, in other words, a possible effective treatment for peanut allergy. The inclusion of a probiotic has been postulated to enhance the tolerogenic effect of OIT.
| Study Summary | |
|---|---|
| Study name | Probiotic and Peanut Oral Immunotherapy Studies |
| Study abbreviation | PPOIT |
| Current principal investigator/s |
Mimi Tang Paxton Loke |
| Current project manager |
Julie Burns |
| Primary Institution/s |
The Royal Children’s Hospital - RCH
Murdoch Children’s Research Institute - MCRI |
| Collaborating Institution/s |
Perth Children’s Hospital - including Princess Margaret Hospital for Children Women and Children’s Hospital Adelaide |
| Major funding source/s |
National Health and Medical Research Council - NHMRC
Murdoch Children’s Research Institute - MCRI Food Allergy and Anaphylaxis Network - FAAN |
| Study website | https://www.foodallergyresearch.org.au/researchers/food-allergy-studies/ppoit-003/ |
| Key reference for study | Tang, M.L., Ponsonby, A.-L., Orsini, F., Tey, D., Robinson, M., Su, E.L., Licciardi, P., Burks, W. and Donath, S. (2015). Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol. 135(3): 737-44.e8. doi: 10.1016/j.jaci.2014.11.034 |
| Study focus |
The PPOIT (probiotic and peanut oral immunotherapy) trials are a series of studies investigating the use of the probiotic Lactobacillus rhamnosus and peanut OIT to induce sustained unresponsiveness to peanut, in other words, a possible effective treatment for peanut allergy. |
| Sampling frame |
Children with clinically proven peanut allergy were recruited through the Royal Children’s Hospital (Melbourne) Department of Allergy/Murdoch Children's Research Institute (RCH/MCRI), also through Immunology outpatient clinics and the general community through media. For PPOIT-3, participants were also recruited from the Women’s and Children’s Hospital Adelaide and Perth Children’s Hospital / Princess Margaret Hospital. |
| Primary study type | Randomised Control Trial / Other trial |
| Year commenced |
2008 |
| Is this study ongoing? | Yes - the study is ongoing |
| Ongoing recruitment? | No |
| Sample size (N) |
PPOIT-1: 62; PPOIT-2: 20; PPOIT-3: 201; PPOIT-3LT: 151. |
| Survey data available? | Yes |
| Imaging data available? | No |
| Linkage to administrative dataset/s? | Yes, linkage to (at least one) administrative dataset underway |
| Biosamples available? | Yes |
| Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? | No |
| Are there any costs associated with data/sample access for approved requests? | There may be costs associated with access, evaluated on a case by case basis |
| Broadest type of participant consent available |
Specific consent (can be used for this project only) |
| Study Contacts | |
|---|---|
| Principal investigator/s |
Mimi Tang Paxton Loke |
| Project manager |
Julie Burns |
| Study Contact |
Email: peanut.study@mcri.edu.au |